A phase I trial of tocoferol monoglucoside in patients undergoing hemi-body radiation.
J Cancer Res Ther
;
2005 Jan-Mar; 1(1): 38-40
Artigo
em Inglês
| IMSEAR
| ID: sea-111401
ABSTRACT
PURPOSE:
To evaluate Tocoferol monoglucoside (TMG), a water soluble vit. E. in a phase I trial, as a radiation protector in those undergoing hemi-body radiation for disseminated disease. MATERIALS ANDMETHODS:
Patients scheduled to receive modified hemi-body radiation were accrued for the study. Patients not only had disseminated skeletal disease but, were heavily pretreated Seven patients were accrued for the study. Patients received 1 and 2 gms of TMG. 30-40 minutes before hemibody radiation. A dose of 600 cGy was delivered on telecobalt equipment at mid plane. Immediate Toxicities were evaluated as well as response to pain.RESULTS:
All the seven patients underwent radiation uneventfully. There was no drug related toxicity. Pain relief was adequate.CONCLUSION:
Tocoferol monoglucoside an effective antioxidant with no significant acute toxicity, when administered in a dose of 1 or 2 gms per oral route. TMG being water-soluble can have global antioxidant and radio protective effects. This needs further clinical evaluation.
Texto completo:
DisponíveL
Índice:
IMSEAR (Sudeste Asiático)
Assunto principal:
Neoplasias da Próstata
/
Protetores contra Radiação
/
Neoplasias da Mama
/
Idoso
/
Humanos
/
Masculino
/
Irradiação Hemicorpórea
/
Adulto
/
Tocoferóis
/
Glucosídeos
Idioma:
Inglês
Revista:
J Cancer Res Ther
Assunto da revista:
Neoplasms
/
Therapeutics
Ano de publicação:
2005
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS